Acute ischemic stroke
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age >=18 years; 2. Diagnosis of acute ischemic stroke confirmed by cranial CT or MRI; 3. Onset-to-enrollment time <=48 hours; 4. Pre-stroke mRS <=1; 5. No mechanical thrombectomy or intra-arterial thrombolysis before enrollment; 6. Written informed consent provided by the patient or legal representative; 7. Agreement to clinical data collection, blood sampling, and 90-day follow-up; 8. Receipt of standard stroke management during the study period, with or without edaravone dexborneol according to random allocation.
Exclusion criteria
Exclusion criteria: 1. Imaging-confirmed acute intracranial hemorrhagic disease; 2. Intra-arterial thrombolysis or mechanical thrombectomy; 3. Pregnancy, lactation, or planned pregnancy within 90 days; 4. Severe renal dysfunction (e.g., eGFR <30 ml/min); 5. Malignant tumor or severe systemic disease with expected survival <90 days; 6. Active severe infection; 7. Severe psychiatric disorder or dementia preventing informed consent or follow-up; 8. Known allergy or contraindication to edaravone dexborneol or its components; 9. Any other condition judged by the investigators to make the participant unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Rankin Scale (mRS) at 90 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| National Institutes of Health Stroke Scale (NIHSS) score at admission;National Institutes of Health Stroke Scale (NIHSS) score Day7 of admission ;serum miR-126 level at admission;serum miR-126 level Day7 of admission;serum galectin-3 level at admission;serum galectin-3 level Day7 of admission;Barthel Index score at admission;Barthel Index score Day7 of admission; | — |
Countries
China
Contacts
Chengdu Sixth People's Hospital